N/A N=10 Randomized Double-blind Treatment

Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

Acne Scars - Mixed Atrophic and Hypertrophic

Bottom Line

View on ClinicalTrials.gov: NCT04606134 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2023

Primary outcome: Primary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Hybrid fractional laser (Device); Alastin Regenerating Skin Nectar with TriHex Technology (Other); Cetaphil face cream (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Rochester
Primary completion: Jun 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Mean Change From Baseline in Erythema	1.768; 5.596	—
PRIMARY Mean Change From Baseline in Erythema	1.768; 5.596	—
SECONDARY Mean Change in Skin Barrier Function	6.502; 21.59; 2.858; 39.07	—
SECONDARY Number of Participants Who Scored Skin Appearance as no Change, Improved or Much Improved Using the Global Aesthetic Improvement Scale	4; 1; 2; 1; 0; 1	—

Summary

To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.

Eligibility Criteria

Inclusion Criteria

male or females
age 18 and older
with evidence of grade II-III acne scars on the face (mild to moderate) as determined by the Goodman & Baron qualitative global acne scar grading system

Exclusion Criteria

treatment to face with any energy device within 6 months
tanning within 7 days
dermabrasion or chemical peel within 3 months
current use of systemic retinoids
keloidal scaring in the treatment area
use of systemic steroids within 6 months
use of topical products with retinoid, alpha-hydroxyacid, salicylic acid, vitamin C or E within 14 days

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04606134). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.